Formulary Group work programme


Forthcoming submissions 2015

This list is indicative and may be subject to change.

Atomoxetine - SMC 909/13 - in progress. (Indication: treatment of attention-deficit/hyperactivity disorder (ADHD) in adults as part of a comprehensive treatment programme).

Bosutinib - SMC 910/13 - Formulary Group advice will be published by 3rd March 2015. (Indication - treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options).

Brimonidine - SMC 1016/14 - Formulary Group advice will be published by 3rd March 2015. (Indication: the symptomatic treatmet of facial erythema of rosacea in adult patients).

Brentuximab - SMC 845/12 - Formulary Group advice will be published by 3rd March 2015. (Indication: treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL)).

Follitropin alfa - SMC 1025/15 - Formulary Group advice will be published by 3rd March 2015. (Indication: In adult women for: anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomiphene citrate; stimulation of multi-follicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer and zygote intra-fallopian transfer; in association with a luteinising hormone (LH) preparation for the stimulation of follicular development in women with severe LH and follicle-stimulating hormone (FSH) deficiency. In clinical trials these patients were defined by an endogenous serum LH level <1.2 units/L. In adult men for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hCG) therapy.).

Nalmefene - SMC 917/13 - in progress. (Indication: for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms, and who do not require immediate detoxification).

Nepafenac - SMC 813/12 - in progress. (Indication: reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients).

Obinutuzumab - SMC 1008/14 - Formulary Group advice will be published by 3rd March 2015. (Indication: in combination with chlorambucil, obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy).

Ondanestron - SMC 912/13 - in progress. (Indication: in adults: prophylaxis and treatment of acute and delayed nausea and vomiting induced by chemotherapy, and radiotherapy. Prophylaxis and treatment of post-operative nausea and vomiting.
In paediatric populations: management of chemotherapy-induced nausea and vomiting in children aged ≥6 months and prophylaxis and treatment of post-operative nausea and vomiting (PONV) in children aged ≥4 years).

Paclitaxel albumin - SMC 968/14 - Formulary Group advice will be published by 3rd March 2015.(Indication:in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas).

Peginterferon beta 1a - SMC 1018/14 - in progress. (Indication: in adult patients for the treatment of relapsing remitting multiple sclerosis).

Rituximab subcutaneous injection- SMC 975/14- Formulary Group advice will be published by 3rd March 2015.(Indication: for non-Hodgkin's lymphoma (NHL) in adults).

Triamcinolone - FG1 363/14 -Formulary Group advice will be published by 3rd March 2015. (Indication: Cystoid Macular Oedema (CMO)).

Umeclidinium/vilanterol - SMC 978/14 - Formulary Group advice will be published by 3rd March 2015. (Indication: as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END

Previous: Formulary Group | Top | Next: Formulary Group decisions index